Ignite Creation Date:
2025-12-25 @ 5:05 AM
Ignite Modification Date:
2025-12-26 @ 4:08 AM
Study NCT ID:
NCT01516918
Status:
COMPLETED
Last Update Posted:
2014-10-20
First Post:
2012-01-13
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
Sponsor:
Vertex Pharmaceuticals Incorporated
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2012-02
Start Date Type:
None
Primary Completion Date:
2013-09
Primary Completion Date Type:
ACTUAL
Completion Date:
2013-12
Completion Date Type:
ACTUAL
First Submit Date:
2012-01-13
First Submit QC Date:
None
Study First Post Date:
2012-01-25
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2014-10-20
Disp First Post Date Type:
ESTIMATED
Last Update Submit Date:
2014-10-09
Last Update Post Date:
2014-10-20
Last Update Post Date Type:
ESTIMATED